T. I. Ionova^1.2, N. B. Bulieva³, O. Yu. Vinogradova^4,5,6,7, A. K. Golenkov⁸, T. A. Gritsenko⁹, A. V. Zinkovskaya², L. K. Kozlova¹⁰, G. B. Kuchma¹⁰, D. A. Lipatova², E. G. Lomaia¹¹, E. R. Machulaytene¹², T. P. Nikitina^1,2, N. V. Novitskaya^4,5, E. V. Trifonova⁸, E. I. Usacheva^12,14, T. V. Shneider¹⁵

Quality of life and symptoms in patients with chronic myeloid leukemia in chronic phase during target treatment (dasatinib as first and second line therapy) in a real world setting

¹SAINT-PETERSBURG MULTISPECIALITY MEDICAL CENTER, SAINT-PETERSBURG
²MULTINATIONAL CENTER FOR QUALITY OF LIFE RESEARCH, SAINT-PETERSBURG
³IMMANUEL KANT BALTIC FEDERAL UNIVERSITY, KALININGRAD
⁴HEMATOLOGICAL MOSCOW CITY CENTER, MOSCOW
⁵BOTKIN CITY CLINICAL HOSPITAL, MOSCOW
⁶CENTRE OF PEDIATRIC HEMATOLOGY, ONCOLOGY, AND IMMUNOLOGY NAMED AFTER DMITRIY ROGACHEV, MOSCOW
⁷PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY, MOSCOW
⁸VLADIMIRSKII MOSCOW REGIONAL RESEARCH AND CLINICAL INSTITUTE, MOSCOW
⁹SAMARA STATE MEDICAL UNIVERSITY, SAMARA
¹⁰ORENBURG STATE MEDICAL UNIVERSITY, ORENBURG
¹¹FEDERAL ALMAZOV NORTH-WEST MEDICAL RESEARCH CENTER, SAINT-PETERSBURG
¹²OUTPATIENT DEPARTMENT, PAVLOV SAINT-PETERSBURG STATE MEDICAL UNIVERSITY, SAINT-PETERSBURG
¹³R. M. GORBACHEVA MEMORIAL INSTITUTE OF CHILDREN HEMATOLOGY AND TRANSPLANTATION, SAINT-PETERSBURG
¹⁴PAVLOV SAINT-PETERSBURG STATE MEDICAL UNIVERSITY, SAINT-PETERSBURG
¹⁵LENINGRAD REGIONAL CLINICAL HOSPITAL, SAINT-PETERSBURG

The article is focused on systematization of results of two observational prospective multicenter surveys «Quality of life, symptom profile, and adherence to treatment in adult patients with newly diagnosed chronic phase chronic myeloid leukemia receiving dasatinib» (2012–2015) and «Quality of life and symptom profile in imatinib-resistant or -intolerant patients with chronic myeloid leukemia during disease-modifying treatment» (2011–2012).
The analysis was performed on 107 patients with chronic myeloid leukemia in chronic phase receiving tartet treatment with tyrosin-kinase inhibitors 2nd generation (TKI-2). Information regarding of quality of life and symptom profile in patients with chronic myeloid leukemia in chronic phase during first- and second-line targtet treatment with TKI2 is presented.
After 12 months of first-line target treatment positive changes in quality of life were revealed — role physical functioning, pain, vitality, social functioning and role emotional functioning improved. The most remarkable clinically significant improvement was observed for role emotional functioning (51,1 vs. 68,9).
During second-line target treatment significant improvement of vitality, social functioning, mental health, pain and as of Integral Quality of Life Index was demonstrated (p <0,05); other parameters were stable. Decrease of severity of the leading symptoms in CML patients during first- and second-line target treatment with TKIs was registered as well. Quality of life and symptom assessment in patients with chronic myeloid leukemia may contribute to clinical outcomes and thus result in better disease control in accordance with the principles of risk-adaptive therapy.